New Era of Preventing End-Stage Kidney Disease Act
HB1518, the New Era of Preventing End-Stage Kidney Disease Act, would expand federal research, education, and demonstration efforts focused on rare kidney diseases, including primary glomerular disease. The bill directs the National Institute of Diabetes and Digestive and Kidney Diseases to create or support regional Centers of Excellence on Rare Kidney Disease Research through grants and cooperative agreements. These centers would study causes, diagnosis, progression, and treatment; increase public awareness, especially in rural and underserved communities; and provide training and educational resources for clinicians, patients, and families.
The bill also requires the Secretary of Health and Human Services to conduct a study on early detection and treatment of rare kidney disease, including routine urinalysis, kidney biopsy, genetic and genomic testing, APOL1 testing, insurance coverage barriers, access to specialists, and factors affecting patient trust and disease progression. In addition, it expands provider education by adding kidney disease to primary care training priorities and authorizing nephrology fellowships aimed at improving care for populations disproportionately affected by rare kidney disease, including racial and ethnic minorities. The bill further directs Medicare-related experiments and studies to identify treatments that could delay or eliminate the need for dialysis or transplant.
If enacted, the bill would amend the Public Health Service Act and the Social Security Act, creating new federal research and training programs and adding specific kidney-disease-related priorities to existing health workforce and research authorities. It authorizes $6 million annually from FY2026 through FY2030 for the Centers of Excellence and $1 million annually over the same period for the HHS study, while also requiring reports to Congress on findings and recommendations. The bill does not itself change coverage rules, but it explicitly examines insurance and access barriers and could influence future policy through the required reports and experiments.
The overall sentiment reflected in the bill’s sponsorship is strongly supportive and bipartisan, with multiple members from both parties listed as cosponsors. The measure appears framed as a public health and research initiative rather than a partisan policy fight, and the available context shows no recorded committee debate or votes yet. The emphasis on underserved communities, early diagnosis, and reducing progression to dialysis suggests broad appeal among health advocates and patient groups.
Notable points of potential contention include the bill’s federal spending commitments, the use of Medicare and Medicaid-related studies, and the explicit instruction that research should not rely on quality-adjusted life years or disability-adjusted life years in value assessments. That provision reflects concern from disability advocates about discriminatory cost-effectiveness methods, but it could also draw scrutiny from budget analysts or policymakers who favor those tools in health economics. Another possible area of discussion is the bill’s focus on genetic testing, including APOL1, and how such testing should be used, covered, and integrated into clinical practice.
The bill would amend the Public Health Service Act to establish NIDDK Centers of Excellence on Rare Kidney Disease Research, authorize related grants and cooperative agreements, and add new federal research, education, and outreach activities focused on rare kidney disease. It would also amend the Social Security Act to require Medicare-related experiments and a study on methods to delay or eliminate dialysis and transplant, while directing HHS to study diagnosis, prevention, treatment, access, and patient trust issues. The bill authorizes new appropriations and would likely expand federal involvement in nephrology research, workforce training, and rare disease awareness, especially for rural, underserved, and disproportionately affected populations.
The bill appears to have broadly positive and bipartisan support, as shown by its list of cosponsors from both parties and its public health framing. There is no recorded vote or committee transcript in the provided context, so there is no evidence of organized opposition at this stage. The measure is presented as a research-and-access initiative aimed at improving outcomes for patients with rare kidney disease and preventing progression to end-stage kidney disease.
The main areas of possible contention are funding levels, the scope of federal research and demonstration authority, and the bill’s treatment of health economics. The prohibition on using quality-adjusted life years or disability-adjusted life years in assessments is likely to be welcomed by disability advocates but could be controversial among analysts who rely on those measures for cost-effectiveness review. There may also be debate over genetic testing policy, including APOL1 testing, insurance coverage, and how to balance expanded screening with privacy, access, and implementation concerns. No specific objections are recorded in the provided committee materials.